Product Description: LRRK2-IN-1 is a potent and selective?LRRK2?inhibitor with?IC50?of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.
Applications: Cancer-Kinase/protease
Formula: C31H38N8O3
References: [1]Hermanson SB, et al. Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation.PLoS One. 2012;7(8):e43580. Epub 2012 Aug 28./[2]Deng, Xianming., et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology (2011), 7(4), 203-205./[3]Koshibu K, et al. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease. Pharmacology. 2015;96(5-6):240-7./[4]Weygant N, et al. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer. 2014 May 6;13:103.
CAS Number: 1234480-84-2
Molecular Weight: 570.69
Compound Purity: 99.42
Research Area: Neurological Disease; Cancer
Solubility: DMSO : 30 mg/mL (ultrasonic)
Target: Apoptosis;LRRK2
Deutsch
English
